Wangrui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wangrui Liu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Abhimanyu Thakur
Pritzker School of Molecular Engineering, Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA
2 shared publicationsKui Zhang
Pritzker School of Molecular Engineering, Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA
2 shared publications- Yuanliang Yan
Department of Pharmacy, The Hunan Institute of Pharmacy Practice and Clinical Research, Xiangya Hospital, Central South University, Changsha, China
2 shared publications Zhijie Xu
Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
2 shared publications- Jiang-Jiang Qin
Center for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
1 shared publication - Ming Gao
State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China
1 shared publication
Latest Publications
- Open Access
- 25 April 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 277, 116372
Effects and mechanisms of N6-methyladenosine RNA methylation in environmental pollutant-induced carcinogenesis
- 25 April 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 277, 116372
Open AccessEffects and mechanisms of N6-methyladenosine RNA methylation in environmental pollutant-induced carcinogenesis
- Top Cited PapersOpen Access
- 7 January 2024
- Published by Springer Nature in Biomarker Research
- Vol. 12 (1) , 1-22
Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
The cGAS-STING signaling pathway has emerged as a critical mediator of innate immune responses, playing a crucial role in improving antitumor immunity through immune effector responses. Targeting the cGAS-STING pathway holds promise for overcoming immunosuppressive tumor microenvironments (TME) and promoting effective tumor elimination. However, systemic administration of current STING agonists faces challenges related to low bioavailability and potential adverse effects, thus limiting their clinical applicability. Recently, nanotechnology-based strategies have been developed to modulate TMEs for robust immunotherapeutic responses. The encapsulation and delivery of STING agonists within nanoparticles (STING-NPs) present an attractive avenue for antitumor immunotherapy. This review explores a range of nanoparticles designed to encapsulate STING agonists, highlighting their benefits, including favorable biocompatibility, improved tumor penetration, and efficient intracellular delivery of STING agonists. The review also summarizes the immunomodulatory impacts of STING-NPs on the TME, including enhanced secretion of pro-inflammatory cytokines and chemokines, dendritic cell activation, cytotoxic T cell priming, macrophage re-education, and vasculature normalization. Furthermore, the review offers insights into co-delivered nanoplatforms involving STING agonists alongside antitumor agents such as chemotherapeutic compounds, immune checkpoint inhibitors, antigen peptides, and other immune adjuvants. These platforms demonstrate remarkable versatility in inducing immunogenic responses within the TME, ultimately amplifying the potential for antitumor immunotherapy.
- 7 January 2024
- Published by Springer Nature in Biomarker Research
- Vol. 12 (1) , 1-22
Top Cited PapersOpen AccessNanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
The cGAS-STING signaling pathway has emerged as a critical mediator of innate immune responses, playing a crucial role in improving antitumor immunity through immune effector responses. Targeting the cGAS-STING pathway holds promise for overcoming immunosuppressive tumor microenvironments (TME) and promoting effective tumor elimination. However, systemic administration of current STING agonists faces challenges related to low bioavailability and potential adverse effects, thus limiting their clinical applicability. Recently, nanotechnology-based strategies have been developed to modulate TMEs for robust immunotherapeutic responses. The encapsulation and delivery of STING agonists within nanoparticles (STING-NPs) present an attractive avenue for antitumor immunotherapy. This review explores a range of nanoparticles designed to encapsulate STING agonists, highlighting their benefits, including favorable biocompatibility, improved tumor penetration, and efficient intracellular delivery of STING agonists. The review also summarizes the immunomodulatory impacts of STING-NPs on the TME, including enhanced secretion of pro-inflammatory cytokines and chemokines, dendritic cell activation, cytotoxic T cell priming, macrophage re-education, and vasculature normalization. Furthermore, the review offers insights into co-delivered nanoplatforms involving STING agonists alongside antitumor agents such as chemotherapeutic compounds, immune checkpoint inhibitors, antigen peptides, and other immune adjuvants. These platforms demonstrate remarkable versatility in inducing immunogenic responses within the TME, ultimately amplifying the potential for antitumor immunotherapy.